Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
Humans
Cholangiocarcinoma
/ drug therapy
Quinolines
/ therapeutic use
Male
Phenylurea Compounds
/ therapeutic use
Female
Middle Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Aged
Bile Duct Neoplasms
/ drug therapy
Gemcitabine
Infusions, Intra-Arterial
Adult
Treatment Outcome
Immune Checkpoint Inhibitors
/ therapeutic use
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Deoxycytidine
/ analogs & derivatives
Cisplatin
/ administration & dosage
Progression-Free Survival
Hepatic arterial infusion chemotherapy
Immunotherapy
Intrahepatic cholangiocarcinoma
Targeted therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
05
05
2024
accepted:
01
10
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
13
10
2024
Statut:
epublish
Résumé
This research was intended to compare the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) in conjunction with lenvatinib and PD1 inhibitors to first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma(ICC). The research enrolled advanced ICC patients who underwent HAIC plus lenvatinib and PD1 inhibitor(n = 51) or first-line systemic chemotherapy(cisplatin + gemcitabine, n = 39) between July 2020 to January 2023 in Zhongshan People's Hospital.Their clinical outcomes were assessed through measurement of parameters encompassing objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), median progression-free survival (mPFS), median duration of response (mDOR), and treatment-related adverse events (TRAEs). In accordance with the RECIST1.1, the ORR in the HAIC + L + P and SC groups was 43.1% and 20.5%, while the DCR was 90.2% and 69.2%, respectively (P = 0.04 and = 0.02, respectively). The change in the maximum diameter of intrahepatic target lesions in patients before and after treatment and the diameter of intrahepatic tumors in the HAIC + L + P group were sharply smaller versus the SC group ( P < 0.001). The HAIC + L + P group had prolonged mOS (16.8 months vs. 11.0 months, P = 0.01) and mPFS (12.0 months vs. 6.9 months, P < 0.01) in comparison with the SC group. Compared to first-line systemic chemotherapy(cisplatin + gemcitabine), HAIC plus lenvatinib and PD-1 inhibitors contributes to improvement of tumor response and prolongation of OS and PFS in advanced ICC patients.
Identifiants
pubmed: 39397104
doi: 10.1038/s41598-024-75102-z
pii: 10.1038/s41598-024-75102-z
doi:
Substances chimiques
lenvatinib
EE083865G2
Quinolines
0
Phenylurea Compounds
0
Gemcitabine
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Deoxycytidine
0W860991D6
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23961Informations de copyright
© 2024. The Author(s).
Références
Florio, A. A. et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 126, 2666–2678 (2020).
doi: 10.1002/cncr.32803
pubmed: 32129902
Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95–111 (2018).
doi: 10.1038/nrclinonc.2017.157
Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557–588 (2020).
doi: 10.1038/s41575-020-0310-z
pubmed: 32606456
pmcid: 7447603
Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl. J. Med. 362, 1273–1281 (2010).
doi: 10.1056/NEJMoa0908721
pubmed: 20375404
Fiteni, F. et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 3, 1502–1511 (2014).
doi: 10.1002/cam4.299
pubmed: 25111859
pmcid: 4298376
Ishii, M., Itano, O., Morinaga, J., Shirakawa, H. & Itano, S. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS One. 17, e0266707 (2022).
doi: 10.1371/journal.pone.0266707
pubmed: 35452492
pmcid: 9032372
Ueno, M. et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. BMC Cancer. 20, 1105 (2020).
doi: 10.1186/s12885-020-07365-4
pubmed: 33198671
pmcid: 7667859
Deng, M. et al. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann. Med. 54, 803–811 (2022).
doi: 10.1080/07853890.2022.2048416
pubmed: 35272564
pmcid: 8920361
Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950–1958 (2019).
doi: 10.1093/annonc/mdz402
pubmed: 31566666
Ensminger, W. D. & Gyves, J. W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 10, 176–182 (1983).
pubmed: 6346495
Ensminger, W. D. et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res. 38, 3784–3792 (1978).
pubmed: 151583
Wang, X. et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology. 283, 580–589 (2017).
doi: 10.1148/radiol.2016160572
pubmed: 27820684
Cercek, A. et al. Assessment of hepatic arterial infusion of Floxuridine in Combination with systemic gemcitabine and oxaliplatin in patients with Unresectable Intrahepatic Cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 6, 60–67 (2020).
doi: 10.1001/jamaoncol.2019.3718
pubmed: 31670750
Tohyama, O. et al. Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 638747 (2014). (2014).
Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).
doi: 10.1016/S1470-2045(20)30109-1
pubmed: 32203698
pmcid: 8461541
Oh, D. Y. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. American Society of Clinical Oncology. (2022).
Shi, G. M. et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study. Signal. Transduct. Target. Ther. 8, 106 (2023).
doi: 10.1038/s41392-023-01317-7
pubmed: 36928584
pmcid: 10020443
Zhang, T. et al. Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: A multicenter retrospective study. Am. J. Cancer Res. 12, 3455–3463 (2022).
pubmed: 35968352
pmcid: 9360239
Cheu, J. W. & Wong, C. C. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology. 74, 2264–2276 (2021).
doi: 10.1002/hep.31840
pubmed: 33811765
Moreno-Cubero, E. & Larrubia, J. R. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J. Gastroenterol. 22, 6469–6483 (2016).
doi: 10.3748/wjg.v22.i28.6469
pubmed: 27605882
pmcid: 4968127
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288–306 (2020).
doi: 10.1016/j.jhep.2019.09.026
pubmed: 31954493
Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90–92 (2021).
doi: 10.1016/j.ad.2019.05.009
pubmed: 32891586